以表皮生長因子受體酪氨酸激酶抑制劑（EGFR-TKI）為代表的分子靶向藥物治療腫瘤，可明顯延長非小細胞肺癌患者的無進展生存期和改善患者的生活質量，但面臨耐藥以及耐藥后如何繼續(xù)治療等問題。闡述EGFR-TKI的作用機制和獲得性耐藥機制，分別對耐藥后快速進展、緩慢進展和局部進展3種進展情況提出了診療意見，以期為改善耐藥、加強療效提供借鑒。

On the behalf of molecule targeted drugs, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) can prolong the progression free survival and improve life quality of non-small-cell lung cancer patients, yet the drug-resisitance and treatment after can not be ignored. State the mechanism of EGFR-TKI and acquired drug-resistance, provide treatment opinions for rapid progress, slow progress and local advancement, meanwhile achieving the target of reversing drug-resistance and strengthening curative effect.

天津市高等學?？萍及l(fā)展基金計劃項目（20110223）